WHO discontinues hydroxychloroquine and lopinavir/ritonavir
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
WHO has pulled hydroxychloroquine and HIV treatment combination lopinavir/ritonavir from their ongoing COVID-19 Solidarity trials, after a recommendation from the international Steering Committee advising the same.

The Committee's recommendation comes after mounting evidence comparing HCQ and lopinavir/ritonavir with standard-of-care treatment from the Trial's interim results, WHO said in a press release.

Hydroxychloroquine and lopinavir/ritonavir produced little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care, the trial concluded.

The decision only applies to WHO's Solidarity trial and doesn't rule out its use in other studies to treat non-hospitalized patients, or as a pre- or post-exposure preventive treatment for COVID-19, the release clarified.

Source: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
N●●●●a C●●●●●n and 3 others like this5 shares
Like
Comment
Share